Triple threat: new drug cocktail aims to extend life in elderly lung cancer
NCT ID NCT05685550
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a combination of three drugs—oral etoposide (chemotherapy), anlotinib (targeted therapy), and envafolimab (immunotherapy)—as a first treatment for elderly patients with extensive small cell lung cancer. The study will enroll 30 participants to see if the combo helps keep the cancer from growing longer than expected. Researchers are also watching for side effects and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of oral etoposide (chemotherapy), anlotinib (targeted therapy), and envafolimab (immunotherapy)
- What this could lead to
- If successful, this could offer a new, more effective first-line treatment option for elderly patients with extensive small cell lung cancer, potentially improving how long they live without the cancer growing.
- What could go wrong
- This is a small, early-phase (phase 2) study with only 30 patients and no comparison group, so results may not apply broadly. The combination of three drugs also raises the risk of serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Cancer Hospital Airport Hospital
Tianjin, 300450, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.